(NASDAQ: ILMN) Illumina's forecast annual revenue growth rate of 5.08% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.6%.
Illumina's revenue in 2024 is $4,504,000,000.On average, 5 Wall Street analysts forecast ILMN's revenue for 2024 to be $717,731,278,600, with the lowest ILMN revenue forecast at $714,891,100,000, and the highest ILMN revenue forecast at $720,119,386,700. On average, 5 Wall Street analysts forecast ILMN's revenue for 2025 to be $793,876,158,600, with the lowest ILMN revenue forecast at $764,309,000,000, and the highest ILMN revenue forecast at $817,340,286,000.
In 2026, ILMN is forecast to generate $856,289,059,500 in revenue, with the lowest revenue forecast at $845,665,800,000 and the highest revenue forecast at $866,912,319,000.